echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Scientists discover new therapeutic targets for poor prognostic subtypes of ovarian cancer

    Scientists discover new therapeutic targets for poor prognostic subtypes of ovarian cancer

    • Last Update: 2021-09-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The inactivating mutation of the ARID1A tumor suppressor gene is the genetic driver of OCCC.


    "The goal of our research is to discover the molecular changes caused by ARID1A deletion, so that we can target them to achieve effective treatment of this devastating disease," Dr.


    The endoplasmic reticulum (ER) is a cellular structure that monitors protein production and has a complex mechanism to deal with the stress caused by the accumulation of misfolded proteins


    The IRE1a/XBP1 pathway is the main signaling pathway of the endoplasmic reticulum stress response


    Zhang and colleagues found that ARID1A inhibits the IRE1a/XBP1 pathway.


    "In some cases, the favorable mechanisms used by cancer cells also make them vulnerable because they become dependent on certain pathways," Zhang added


    Importantly, this observation was confirmed in vivo, because B-I09 treatment reduced the tumor burden in arid1a inactivated ovarian tumor mouse model and improved survival


    Therapeutic resistance allows cancer cells to escape the effects of single-drug therapy, and the combined strategy provides a solution to this major challenge


    "Our results show that the pharmacological inhibition of the IRE1a/XBP1 pathway of the endoplasmic reticulum stress response, alone or in combination with HDAC6 inhibition, represents a potential treatment strategy for arid1a mutant cancers," said Joseph Zundell, who is Zhang A pre-doctoral trainee in the laboratory is also the first author of this paper


    Journal Reference :

    1. Joseph A.



    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.